In-Vivo Antihyperlipidemic Potentials Of Guggul Lipid Loaded Chitosan Nanoparticles Designed And Optimized By Box-Behnken Design

Abstract

Oral application of guggul lipid for the treatment of hyperlipidaemia/obesity is limited due to extensive hepatic metabolism and lack of suitable drug delivery carriers/systems.

Guggul lipid loaded chitosan nanoparticles (GNPs) were designed, optimized and evaluated to address the above mentioned limitations. GNPs were designed, optimized by three factor-three level Box-Behnken experimental design employing ionic gelation technique. Further GNPs were evaluated for in-vitro characteristics and in-vivo parameters like assessment of body weight, lipid profile like triglycerides, total cholesterol, high density lipoproteins, low density lipoproteins, very low density lipoproteins along with atherogenic index and total protein in obese rats using high fat diet induced model. GNPs produced better in-vitro characteristics with high entrapment efficiency (92.98 ± 0.47%) and desired biphasic drug release (95.12 ± 0.36%) with additional in-vitro lipase inhibition and cell viability respectively. Oral administration of GNPs displayed promising in-vivo potentials with significant (p<0.05) reduction of body weight and lipid levels along with increased levels of high density lipoproteins and total proteins in obese rats at the end of 28^th day. Histopathological examinations of liver and adipose tissues of GNPs treated rat’s revealed normal architecture as that of normal group rats. Conclusively GNPs were found to be promising nanocarriers for effective treatment of hyperlipidaemia/obesity and related disorders like atherosclerosis.